Jointly provided by:	Supported by an independent educational grant from Bristol-Myers Squibb.
This webcast now has a free archived version available with credit for physicians, pharmacists, and nurses. Click here to access. The Managed Care Review BoardTM - Analyzing the Latest Advancements for the Treatment of Chronic Myelogenous Leukemia
Live Webcast Dates
Monday, October 5th     1:00 - 3:00 pm ET Wednesday, October 28th     1:00 - 3:00 pm ET
Distinguished Multi-Disciplinary Faculty Presenters
Jeffrey Dunn, PharmD, MBA Senior Vice President Chief Clinical Officer VRx Pharmacy Services, LLC Christopher Fausel, PharmD, BCPS, BCOP Clinical Manager, Oncology Pharmacy Clinical Pharmacist, Hematology-Oncology-BMT Indiana University Simon Cancer Center Indiana University Health Elias Jabbour, MD Associate Professor Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Fadia Tohme-Shaya, PhD, MPH Professor and Vice-Chair for Academic Affairs PHSR University of Maryland School of Pharmacy
Hot Topics Include:
Benefits of regular and ongoing hematologic and cytogenetic analyses in the management of CML as a means of adjusting treatment plans Information on emerging/investigational therapies and clinical trials of existing agents in novel treatment settings Innovative oncology pharmacy benefit models and specialty pharmacy management services for oral TKI therapies
Target Audience:
Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs) Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for chronic myelogenous leukemia (CML) including: physicians, pharmacists, registered nurses, and case managers
Statement of Need:
Hematologists, nurses, and oncology pharmacists who care for patients with hematologic malignancies are challenged with determining appropriate treatment sequences and combinations, and obtaining treatment coverage and reimbursement. Given the rising costs of cancer care, these health care professionals must appreciate not only new products' clinical data and role; they must also be cognizant of the financial consequences of their cancer care recommendations. Because they are responsible for evaluating coverage and reimbursement decisions, managed care personnel also need a solid understanding of clinical data supporting the use of targeted cancer agents, as well as data regarding the integration of these agents into hematologists' clinical practices.
Educational Objectives:
After completing this activity, the participant should be better able to: Characterize the benefits of regular and ongoing hematologic and cytogenetic analyses in the management of CML as a means of adjusting treatment plans and maintaining the most appropriate and effective therapy for all patients at all times Promote benefit design structures that allow for liberal but judicious use of hematologic and cytogenetic analyses on the part of clinicians treating patients with CML in addition to coverage parameters that integrate the results of said analyses in choosing the most appropriate therapy Facilitate a care partnership by providing complete, accurate, and understandable counsel to patients with CML-including information on emerging/investigational therapies and clinical trials of existing agents in novel treatment settings-as part of the managed care and hematology/oncology treatment team Integrate innovative oncology pharmacy benefit models and specialty pharmacy management services for oral TKI therapies that enhance accessibility and promote medication adherence Further encourage medication persistence with oral TKI therapies by implementing prescription logs/medication diaries to thoroughly monitor drug utilization and aggressively manage toxicities Provide accurate and appropriate counsel as part of the managed care treatment team Provide appropriate care and counsel for patients and their families
Webcast Agenda:
Introduction Assessing the Clinical Benefits of Current and Evolving CML Therapies in a Managed Care Setting Elias Jabbour, MD Current Practice Guidelines Review Christopher Fausel, PharmD, BCPS, BCOP Faculty Idea Exchange Analyzing the Available Data to Assess the Value of Current and Emerging Treatment Options Fadia T. Shaya, PhD, MPH Plan Benefit Designs: Maximizing Value for Current and Emerging CML Therapies Jeffrey Dunn, PharmD, MBA Faculty Idea Exchange Q&A Session Closing Commentary
Accreditation:
Physician Continuing Education This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Pharmacist Continuing Education Pharmacist Accreditation Statement Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Credit Designation Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0809-9999-15-229-L01-P Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks. Type of Activity: Application
Nursing Continuing Education Credit Designation This educational activity for 2.0 contact hours is provided by Postgraduate Institute for Medicine. Accreditation Statement Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. A statement of credit will be issued only upon receipt of a completed activity evaluation form.
Hardware/Software Requirements:
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.x, and Google Chrome 10 and up
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Policy on Privacy and Confidentiality:
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Fee Information:
No additional fee is required to attend this CPE/CME/CNE activity.
Questions:
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.